Arch Biopartners Stock Working Capital
ARCH Stock | CAD 1.77 0.05 2.91% |
Arch Biopartners fundamentals help investors to digest information that contributes to Arch Biopartners' financial success or failures. It also enables traders to predict the movement of Arch Stock. The fundamental analysis module provides a way to measure Arch Biopartners' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Arch Biopartners stock.
Last Reported | Projected for Next Year | ||
Net Working Capital | -4.3 M | -4.1 M | |
Change In Working Capital | 241.1 K | 253.2 K |
Arch | Working Capital |
Arch Biopartners Company Working Capital Analysis
Arch Biopartners' Working Capital is a measure of company efficiency and operating liquidity. The working capital is usually calculated by subtracting Current Liabilities from Current Assets. It is an important indicator of the firm ability to continue its normal operations without additional debt obligations. .
More About Working Capital | All Equity Analysis
Working Capital | = | Current Assets | - | Current Liabilities |
Current Arch Biopartners Working Capital | (4.81 M) |
Most of Arch Biopartners' fundamental indicators, such as Working Capital, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Arch Biopartners is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Arch Working Capital Driver Correlations
Understanding the fundamental principles of building solid financial models for Arch Biopartners is extremely important. It helps to project a fair market value of Arch Stock properly, considering its historical fundamentals such as Working Capital. Since Arch Biopartners' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Arch Biopartners' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Arch Biopartners' interrelated accounts and indicators.
Click cells to compare fundamentals
Working Capital can be positive or negative, depending on how much of current debt the company is carrying on its balance sheet. In general terms, companies that have a lot of working capital will experience more growth in the near future since they can expand and improve their operations using existing resources. On the other hand, companies with small or negative working capital may lack the funds necessary for growth or future operation. Working Capital also shows if the company has sufficient liquid resources to satisfy short-term liabilities and operational expenses.
Competition |
Arch Net Invested Capital
Net Invested Capital |
|
In accordance with the company's disclosures, Arch Biopartners has a Working Capital of (4.81 Million). This is 101.13% lower than that of the Biotechnology sector and 100.89% lower than that of the Health Care industry. The working capital for all Canada stocks is 100.33% higher than that of the company.
Arch Working Capital Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Arch Biopartners' direct or indirect competition against its Working Capital to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Arch Biopartners could also be used in its relative valuation, which is a method of valuing Arch Biopartners by comparing valuation metrics of similar companies.Arch Biopartners is currently under evaluation in working capital category among its peers.
Arch Biopartners Current Valuation Drivers
We derive many important indicators used in calculating different scores of Arch Biopartners from analyzing Arch Biopartners' financial statements. These drivers represent accounts that assess Arch Biopartners' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Arch Biopartners' important valuation drivers and their relationship over time.
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Market Cap | 82.1M | 104.9M | 187.1M | 6.8M | 6.1M | 5.8M | |
Enterprise Value | 84.8M | 109.6M | 191.0M | 8.5M | 7.6M | 7.2M |
Arch Fundamentals
Return On Asset | -0.81 | ||||
Profit Margin | (1.86) % | ||||
Operating Margin | (1.39) % | ||||
Current Valuation | 119.89 M | ||||
Shares Outstanding | 64.94 M | ||||
Shares Owned By Insiders | 19.86 % | ||||
Number Of Shares Shorted | 3.97 K | ||||
Price To Sales | 83.08 X | ||||
Revenue | 1.98 M | ||||
Gross Profit | (502.88 K) | ||||
EBITDA | (5.24 M) | ||||
Net Income | (3.33 M) | ||||
Cash And Equivalents | 72.82 K | ||||
Total Debt | 5.02 M | ||||
Current Ratio | 0.32 X | ||||
Book Value Per Share | (0.10) X | ||||
Cash Flow From Operations | (234.07 K) | ||||
Short Ratio | 0.29 X | ||||
Earnings Per Share | (0.03) X | ||||
Beta | 1.39 | ||||
Market Capitalization | 129.88 M | ||||
Total Asset | 1.17 M | ||||
Retained Earnings | (28.05 M) | ||||
Working Capital | (4.81 M) | ||||
Net Asset | 1.17 M |
About Arch Biopartners Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Arch Biopartners's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Arch Biopartners using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Arch Biopartners based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Arch Stock Analysis
When running Arch Biopartners' price analysis, check to measure Arch Biopartners' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arch Biopartners is operating at the current time. Most of Arch Biopartners' value examination focuses on studying past and present price action to predict the probability of Arch Biopartners' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arch Biopartners' price. Additionally, you may evaluate how the addition of Arch Biopartners to your portfolios can decrease your overall portfolio volatility.